Sara Balduzzi

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.

Journal: Nature medicine

Published: January 12, 2026

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 20, 2025

Comparison of efficacy and toxicity of 2 dactinomycin (ACTD) regimens in the second-line treatment of low-risk gestational trophoblastic neoplasia: a retrospective study.

Comparison of efficacy and toxicity of 2 dactinomycin (ACTD) regimens in the second-line treatment of low-risk gestational trophoblastic neoplasia: a retrospective study.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: October 02, 2025

Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.

Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.

Journal: ESMO open

Published: August 01, 2025

Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).

Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02).

Journal: Breast (Edinburgh, Scotland)

Published: April 18, 2025

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers.

Journal: Nature

Published: January 23, 2025

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

Journal: Nature medicine

Published: July 29, 2024

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.

Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 05, 2024

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.

Journal: JAMA oncology

Published: June 27, 2024

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

Journal: The New England journal of medicine

Published: June 05, 2024

Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [18F]FDG PET/CT: a systematic review and individual patient data meta-analysis.

Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [18F]FDG PET/CT: a systematic review and individual patient data meta-analysis.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 24, 2024

Surgical navigation for targeted retroperitoneal lymph-node removal: a randomised, controlled, phase 3 trial.

Surgical navigation for targeted retroperitoneal lymph-node removal: a randomised, controlled, phase 3 trial.

Journal: EClinicalMedicine

Published: March 22, 2024

Showing 1-12 of 25

Last Updated: 09/26/2026